Intensive therapy with high-dose melphalan (MEL) 280 mg/m2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma.

被引：0
|
作者：
Reece, DE
Vesole, D
Flomenberg, N
Badros, A
Filicko, J
Herzig, R
Howard, DS
Johnson, V
Meisenberg, B
Rapoport, A
Xun, CQ
Phillips, GL
机构：
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Thomas Jefferson Univ, Coll Med, Philadelphia, PA 19107 USA
[4] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Univ Kentucky, Lexington, KY 40506 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1672
引用
收藏
页码：432A / 432A
页数：1
相关论文
共 50 条
  • [11] High-Dose Therapy (HDT) with Melphalan and Autologous Stem Cell Transplantation (ASCT) for Patients Older Than 70 Years with Multiple Myeloma
    Brockhoff, Hendrik
    zum Bueschenfelde, Christian Meyer
    Ayoub, Murwan
    Goldschmidt, Hartmut
    Salwender, Hans-Juergen
    BLOOD, 2016, 128 (22)
  • [12] Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival
    Hari, Parameswaran
    Reece, Donna E.
    Randhawa, Jasleen
    Flomenberg, Neal
    Howard, Dianna S.
    Badros, Ashrof Z.
    Rapoport, Aaron P.
    Meisenberg, Barry R.
    Filicko-Ohara, Joanne
    Phillips, Gordon L.
    Vesole, David H.
    BONE MARROW TRANSPLANTATION, 2019, 54 (02) : 293 - 299
  • [13] Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival
    Parameswaran Hari
    Donna E. Reece
    Jasleen Randhawa
    Neal Flomenberg
    Dianna S. Howard
    Ashrof Z. Badros
    Aaron P. Rapoport
    Barry R. Meisenberg
    Joanne Filicko-Ohara
    Gordon L. Phillips
    David H. Vesole
    Bone Marrow Transplantation, 2019, 54 : 293 - 299
  • [14] Intensive treatment with high-dose melphalan as initial therapy in newly-diagnosed patients with multiple myeloma: key to attain rapid complete remission (CR)
    Powles, R
    Sirohi, B
    Goyal, S
    Treleaven, J
    Sankpal, S
    Lloyd, C
    Rudin, C
    Rao, S
    Kulkarni, S
    BONE MARROW TRANSPLANTATION, 2002, 29 : S97 - S98
  • [15] Safety of High-Dose Melphalan (200 Mg/M2) as Conditioning for Autologous Stem Cell Transplantation for Myeloma in Elderly Patients
    Desai, Amrita
    Beitinjaneh, Amer
    Ramdial, Jeremy
    Ali, Robert
    Lekakis, Lazaros
    Pereira, Denise
    Kimble, Erik
    Florou, Vaia
    Bravo, Gabriela
    Goodman, Mark
    Byrnes, John J.
    Jimenez, Antonio M.
    Saneeymehri, Seyyedeh
    Komanduri, Krishna V.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S127 - S128
  • [16] Glomerular filtration rate prior to high-dose melphalan 200 mg/m2 as a surrogate marker of outcome in patients with myeloma
    Sirohi, B
    Powles, R
    Kulkarni, S
    Rudin, C
    Saso, R
    Rigg, A
    Horton, C
    Singhal, S
    Mehta, J
    Treleaven, J
    BRITISH JOURNAL OF CANCER, 2001, 85 (03) : 325 - 332
  • [17] Multiple myeloma:: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)
    Palumbo, A
    Bringhen, S
    Bertola, A
    Cavallo, F
    Falco, P
    Massaia, M
    Bruno, B
    Rus, C
    Barbui, A
    Caravita, T
    Musto, P
    Pescosta, N
    Rossini, F
    Vignetti, M
    Boccadoro, M
    LEUKEMIA, 2004, 18 (01) : 133 - 138
  • [18] A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT
    W I Bensinger
    P S Becker
    T A Gooley
    T R Chauncey
    D G Maloney
    A K Gopal
    D J Green
    O W Press
    M Lill
    J J Ifthikharuddin
    R Vescio
    L A Holmberg
    G L Phillips
    Bone Marrow Transplantation, 2016, 51 : 67 - 71
  • [19] Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)
    A Palumbo
    S Bringhen
    A Bertola
    F Cavallo
    P Falco
    M Massaia
    B Bruno
    C Rus
    A Barbui
    T Caravita
    P Musto
    N Pescosta
    F Rossini
    M Vignetti
    M Boccadoro
    Leukemia, 2004, 18 : 133 - 138
  • [20] A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT
    Bensinger, W. I.
    Becker, P. S.
    Gooley, T. A.
    Chauncey, T. R.
    Maloney, D. G.
    Gopal, A. K.
    Green, D. J.
    Press, O. W.
    Lill, M.
    Ifthikharuddin, J. J.
    Vescio, R.
    Holmberg, L. A.
    Phillips, G. L.
    BONE MARROW TRANSPLANTATION, 2016, 51 (01) : 67 - 71
12345